Axogen (AXGN)
Supplies nerve grafts and protective implants for surgical peripheral nerve repair.
Something off on this page? Send us feedback.
Sells processed nerve allografts and porcine extracellular-matrix devices that bridge, connect, wrap, and protect damaged peripheral nerves, plus an amniotic soft-tissue barrier. Revenue comes almost entirely from U.S. surgical customers, with Avance contributing most sales and carrying ongoing FDA confirmatory-study obligations.
Develops and commercializes a focused portfolio for surgical repair of damaged peripheral nerves. Avance is an acellular human nerve allograft used to bridge nerve gaps; Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, and Axoguard Nerve Cap connect, wrap, or protect nerves, while Avive+ Soft Tissue Matrix separates and protects tissues around the surgical bed.
Concentrates commercial execution on U.S. hospitals and surgeons serving extremity, oral maxillofacial and head-and-neck, and breast procedures, pairing a direct sales force and surgeon education with clinical research. Products reach Canada and parts of Europe, but nearly all revenue comes from the United States. Avance generates most revenue and depends on donated human tissue. It is now sold as an FDA-licensed biologic, with continued approval for some indications tied to confirmatory studies.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 26, 2026 | Truist Financial | Target | Target: $55 | Target: $60 |
| Jul 30, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $50 | Target: $53 |
| Jul 30, 2026 | Truist Financial | Target | Target: — | Target: $55 |
| Jul 29, 2026 | Jefferies | Reiterate | Rating: —Target: $36 | Target: $55 |
| Apr 29, 2026 | Raymond James | Target | Target: $41 | Target: $48 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $94.6M · Total debt $20.1M · Total assets $304.9M · Shareholders' equity $256.3M
- Revenue
- $69.7M
- Operating income
- −$2.2M
- Net income
- −$1.5M
No dividends on record.
| Institutions | ≈ 96.92% | 52.10M shares | |
|---|---|---|---|
| 260 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.20% | 1.18M shares | |
| 14 holders · as of Sep 4, 2026 | |||
| Other | ≈ 0.88% | 472.5K shares | |
| remainder | |||
53.76M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.22% | 4.42M | as of Jun 30, 2026 |
First Light Asset Management, LLCInstitution | 5.11% | 2.75M | as of Jun 30, 2026 |
Morgan StanleyInstitution | 5.11% | 2.75M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.20% | 2.26M | as of Jun 30, 2026 |
Polar Capital Holdings PLCInstitution | 2.79% | 1.50M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Joseph A. Tyndall | director | −3,500 | $49.70 |
| Aug 11, 2026 | Amy McBride Wendell | director | −13,353 | $48.42 |
| Aug 10, 2026 | Marc A. Began | officer: EVP & General Counsel | −67,500 | $47.35 |
| Aug 7, 2026 | Kathy Johnson Weiler | director | −14,150 | $45.30 |
| May 8, 2026 | Amy McBride Wendell | director | −1,647 | $42.60 |
- Integra LifeSciences
Collagen conduit and wrap products overlap nerve repair.
- Optical Cable
Remplir targets US peripheral nerve repair procedures.
- Baxter International
Synovis Nerbridge conduit overlaps nerve reconstruction.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Axogen | $44.20 | −0.81% | $2.47B | — | 75.3 | 9.8 | +23.1% |
| Integra LifeSciences | $16.02 | +0.06% | $1.21B | — | 6.3 | 0.7 | +0.8% |
| Optical Cable | $14.39 | +1.80% | $130.5M | 50.8 | 17.9 | 1.6 | +22.0% |
| Baxter International | $23.68 | +0.02% | $11.85B | — | 11.2 | 1.0 | +5.3% |
| Median | 50.8 | 11.2 | 1.0 | +5.3% |